Log in or Sign up for Free to view tailored content for your specialty!
Spondyloarthropathies News
ASAS consensus identifies preliminary definitions of ‘flare’ in axSpA
Researchers of an Assessment of Spondyloarthritis initiative have identified 12 preliminary definitions of flare among patients with axial spondyloarthritis using common, validated outcome measures.
Axial, peripheral SpA ASAS criteria predicted SpA diagnosis
Researchers of this study used the positive predictive value of the Assessment of Spondyloarthritis International Society Spondyloarthritis classification criteria to predict diagnosis of the condition by a rheumatologist after 4-year follow-up.
Log in or Sign up for Free to view tailored content for your specialty!
FDA advisory committee unanimously recommends approval of biosimilar to Enbrel
The FDA Arthritis Advisory Committee voted 20-0 in favor of recommending the approval of GP2015, Sandoz’s proposed biosimilar to Amgen’s Enbrel.
Implementation of rapid access clinic linked with better access to rheumatology assessment
Utilization of a rapid access clinic was associated with high diagnostic accuracy and substantial improvement of access to rheumatology assessments, according to results.
Study links childhood appendicitis to lower risk for developing ankylosing spondylitis
LONDON — Although appendicitis during childhood was linked with a decreased risk for the development of ankylosing spondylitis later in life, researchers found respiratory tract infections increased the odds of ankylosing spondylitis.
Factors other than biologics increase costs of early spondyloarthritis
Increased costs related to early spondyloarthritis are due to not only biologics, but also factors such as age, peripheral arthritis and independent disease activity, study investigators found.
Antibodies to biological infliximab cross-reacted with infliximab biosimilars
LONDON — Findings presented at the EULAR Annual Congress showed antibodies to infliximab in patients who received the biological treatment cross-reacted with infliximab biosimilars.
Use of evidence-based approach, consensus process supports adaptation of comorbidities initiative
LONDON — Use of an evidence-based approach and consensus process for the collection and management of the comorbidities and risk factors of chronic inflammatory rheumatic diseases has been shown to support the EULAR initiative on comorbidities at a national level, according to a study presented at the EULAR Annual Congress.
Biogen receives marketing authorization in the EU for infliximab biosimilar
Biogen announced the European Commission granted marketing authorization in the European Union for Flixabi, a biosimilar to infliximab indicated for the treatment of adults with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
High prevalence of radiographic vertebral fractures found among patients with ankylosing spondylitis
Patients with active ankylosing spondylitis had a high prevalence of radiographic vertebral fractures, according to results.
-
Headline News
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
November 26, 20242 min read -
Headline News
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
November 26, 20243 min read -
Headline News
Q&A: How to talk to families about vaccines
November 26, 20245 min read
-
Headline News
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
November 26, 20242 min read -
Headline News
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
November 26, 20243 min read -
Headline News
Q&A: How to talk to families about vaccines
November 26, 20245 min read